Ciomei, M., Zanetta, L., Lussana, F., Ravelli, E., Fiorentini, F., Bosotti, R., et al. (2019). A phase I/II study of NMS-03592088, a FLT3, KIT and CSF1R inhibitor, in patients with relapsed or refractory AML or CMML. Intervento presentato a: 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) - DEC 07-10, 2019, United States, Orlando, FL [10.1182/blood-2019-121954].

A phase I/II study of NMS-03592088, a FLT3, KIT and CSF1R inhibitor, in patients with relapsed or refractory AML or CMML

Cairoli R;
2019

paper
Hematology
English
61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) - DEC 07-10, 2019
2019
2019
134
S1
3855
none
Ciomei, M., Zanetta, L., Lussana, F., Ravelli, E., Fiorentini, F., Bosotti, R., et al. (2019). A phase I/II study of NMS-03592088, a FLT3, KIT and CSF1R inhibitor, in patients with relapsed or refractory AML or CMML. Intervento presentato a: 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) - DEC 07-10, 2019, United States, Orlando, FL [10.1182/blood-2019-121954].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/409359
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 3
Social impact